The fate of nanomedicines in a living system determines their therapeutic efficiency and side effects. To compare the in vivo behaviors of CPBs
2 and SPNPs
2, we labeled the two polymers with radioactive nuclide fluorine-18 (
18F) through the reaction between the amino groups in the polymers and
N-succinimidyl 4-[
18F]fluorobenzoate ([
18F]SFB) and traced the biodistributions of the labeled CPBs
2 and SPNPs
2 by micropositron emission tomography (microPET) at different time points after tail-vein injection, respectively. This image-based technique is used because it can not only provide precise quantitative biodistribution information in a living body but also reduce the interindividual variability since one animal can be imaged at multiple time points. 3D reconstruction of whole-body microPET images at different time points after tail-vein injection of the radio-labeled samples was conducted (Figure
4; Movie S1 and S2), followed by the quantifications of the radioactivities in different tissues. Figure S13 shows the biodistribution profiles of the labeled CPBs
2 and SPNPs
2 in the heart, liver, kidney, and tumor as well as the remnant percentage of the radioactivity in the whole body at different time points after the injection. It is noteworthy that, for either CPBs
2 or SPNPs
2, the concentration of the injected sample in hearts is the highest among all the test organs over the whole monitoring duration. This is quite different from common nanomaterials, since intravenously injected nanomaterials generally exhibit high liver and spleen uptakes due to the opsonization-induced reticuloendothelial system (RES) capture. The signals acquired in heart region include the signals from blood. The high concentrations of CPBs
2 and SPNPs
2 in hearts may be associated with their long retention time in bloodstream due to the high density of PEG chains on their surface. At 5 min postinjection (p.i.), the concentrations in hearts are 16.3% and 16.9% injected dose per gram of tissue (ID/g) for CPBs
2 and SPNPs
2, respectively. Thereafter, their concentrations in hearts decrease gradually as time goes by, and at 8 h p.i., the concentrations are 10.7% and 13.3% ID/g for CPBs
2 and SPNPs
2, respectively (Figure S13A). It can be seen that the concentration of SPNPs
2 in hearts is always higher than that of CPBs
2 over the monitoring period, probably because of the longer blood circulation time of SPNPs
2 than CPBs
2. Significant differences in the liver uptake and liver excretion are also observed between CPBs
2 and SPNPs
2 (Figure S13B). SPNPs
2 show higher concentrations in livers than CPBs
2 at all the test time points except the 5 min point. Within 8 h p.i., the liver uptake of SPNPs
2 increases from 6.4% to 10.3% ID/g gradually, and the liver uptake of CPBs
2 decreases from 7.9% to 5.4% ID/g. The significantly different concentrations of CPBs
2 and SPNPs
2 in livers can be seen clearly from the microPET images in Figure
4 and Movie S1 and S2. In the kidney, at 5 min p.i., the concentration of CPBs
2 is 9.9% ID/g; in contrast, the concentration of SPNPs
2 is 5.7% ID/g. At 8 h p.i., the concentrations of CPBs
2 and SPNPs
2 in the kidney decrease to 4.2% and 5.5% ID/g, respectively (Figure S13C). The comparisons suggest that CPBs
2 are much more susceptible to the hepatobiliary and renal excretion than SPNPs
2. A rapider body clearance of CPBs
2 than SPNPs
2 is also observed (Figure S13D). Notably, in the tumor, their concentrations keep increasing from 5 min to 8 h p.i., and at 8 h p.i., the concentrations of CPBs
2 and SPNPs
2 in tumors are 4.5% and 7.2% ID/g, respectively, suggesting that SPNPs
2 have higher passive tumor targeting ability than CPBs
2 (Figure S13E).